about
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyTRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroidsTRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress ResponseGene expression analysis on the dicyclanil-induced hepatocellular tumors in mice.Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases.Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.MDC1 cleavage by caspase-3: a novel mechanism for inactivating the DNA damage response during apoptosis.Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblastsEnhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rulesParallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.TRAIL promotes caspase-dependent pro-inflammatory responses via PKCδ activation by vascular smooth muscle cells.Potent and tumor specific: arming bacteria with therapeutic proteins.Direct estimation of differential networksExpression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathologicalInterferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumorsRecombinant approaches to IgG-like bispecific antibodies.Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response.TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor developmentOn the TRAIL of a new therapy for leukemia.Following the TRAIL from hepatitis C virus and alcohol to fatty liverThe transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLExpression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Tagged and untagged TRAIL show different activity against tumor cells.Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.TRAIL receptor-targeted therapy.Functional subsets of mouse natural killer cells.BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomasApoptosis pathways as promising targets for skin cancer therapy.Novel antibodies as anticancer agents.Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsThe role of TRAIL death receptors in the treatment of hematological malignancies.The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.
P2860
Q24650617-3A3FF021-57A2-4CD7-B1A5-CC0F58391A5DQ26772347-89303610-79E2-4914-A565-A76DCFADC2C5Q28544399-9C6684AD-A584-4FAF-A43A-684F71E56630Q28548386-406FE554-F7C3-4271-946C-C8D32A4A98EFQ33266197-66B25B0E-16A5-4828-9139-F346A5026A14Q33288897-7C11D389-975E-4150-8690-6F282EEF3AC8Q33523440-384DA0A9-B614-4AC1-B367-4629254C4A85Q33656349-7AC2E7F3-E8C6-4019-9E36-DDD8655EC086Q33726537-8805B215-CE38-4F3A-A9B8-D5783BC21356Q34547788-E7AFD69C-D5A8-4941-B3C3-431C251DF8F0Q35082212-F6BCC573-7D49-4CDD-9402-A0162B0C5366Q35221776-5EA427EF-14C7-47D4-BBC7-69A933E82867Q35551640-7121D06D-9D5D-484C-8A74-18262A6C7334Q35570425-2BCD4869-5DF7-4D56-8DC3-7BE2035BC748Q35572079-3D9A2654-E208-4FF8-99B7-939CE7946704Q35579375-5BC7B2D3-F539-4D9D-9AE6-C1A64BA11764Q35647249-FF7E92BE-87D4-40AC-B825-0B3FBBE3732FQ35770122-97D83823-F867-4EF8-B3DC-D868119379D8Q35855534-FB9E4110-4E7C-4C7F-BCE6-FA9ED789467BQ36087611-5FECBB8D-6F7C-45F6-9927-8D5511E36F48Q36139512-75739EAE-3E9B-4539-8CE7-35EA942BCE73Q36167620-4D8F9DF6-0A38-46A3-85CF-8BB9B24B82D4Q36249542-B49740D6-A3E4-4CA5-AA2A-5D3300DAE2FEQ36285964-1761C0C5-EE60-4C8B-AF7A-9DA5A9FEC9F7Q36287589-3FBDFAE7-75F4-4092-A7B7-09D38020F795Q36294675-4CB1B5C7-2159-42F4-A97E-F9EE266958DFQ36338510-64F3E2DF-22D6-4107-9271-79DEF2B6CDE5Q36365504-6FDCC1A6-D1DD-4E8B-9BB8-11501DC315FDQ36424299-920FDAC9-738C-4638-8CA0-1CCD80298FD7Q36491838-C36188BF-86C2-4EAF-9B30-DD9305825924Q36508944-19DA2BAE-2515-4048-9E5D-0AECE455B18DQ36572530-7CF662B5-74C2-46B2-8A22-0518253F8A07Q36652157-046C0CB3-66AE-4D08-A360-CBCF7E2D1F1AQ36809469-D9BEDDF5-7CC4-46FD-A49F-A65C6C4C550BQ36815310-60DF8DE9-C576-4869-9EF1-6B6A63F26779Q36832141-DE406827-38E0-4D20-AD0A-B1A821978596Q37004739-11650E9E-B56C-4908-98AF-B9A34AF95BE3Q37017342-B823DE32-833A-459E-9FEC-2F566545C96DQ37059750-C234A63B-53B6-4F73-97DE-E68F777454F6Q37129891-513BEAFB-0B84-48B6-B361-A206FABB0F46
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
TRAIL and its receptors as targets for cancer therapy.
@ast
TRAIL and its receptors as targets for cancer therapy.
@en
type
label
TRAIL and its receptors as targets for cancer therapy.
@ast
TRAIL and its receptors as targets for cancer therapy.
@en
prefLabel
TRAIL and its receptors as targets for cancer therapy.
@ast
TRAIL and its receptors as targets for cancer therapy.
@en
P2093
P2860
P1433
P1476
TRAIL and its receptors as targets for cancer therapy.
@en
P2093
Kazuyoshi Takeda
Ko Okumura
Yoshihiro Hayakawa
P2860
P304
P356
10.1111/J.1349-7006.2004.TB02181.X
P577
2004-10-01T00:00:00Z